Ligand Pharmaceuticals Director Unloads 2,501 Shares — Should You Be Concerned?
This biotech innovator, known for its royalty-driven model, reported a notable insider sale amid a period of strong share price gains.
Ligand Pharmaceuticals Director Unloads 2,501 Shares — Should You Be Concerned?
Overview
Director John W. Kozarich reported the sale of 2,501 shares of Ligand Pharmaceuticals (NASDAQ:LGND) in open-market transactions from May 1, 2026 through May 13, 2026, according to a SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average purchase price ($225.14); post-transaction value based on May 13, 2026 market close ($221.21).
Details
* 1-year price change calculated using June 12th, 2026 as the reference date.
Source
Originally published at www.fool.com.
Related Articles
- Elon Musk drifted from Larry Page over a decade ago, but their companies are closer than ever
- Prem Watsa Adds 1.2 million to Under Armour shares — Is the Turnaround Finally Worth a Look?
- Social Security Is Scheduled to Run Out of Money Sooner Than Previously Expected, and President Trump Is Partly to Blame
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.
